본문바로가기
Q
U
I
C
K

Business

SK bioscience’s effort reaches beyond the development and manufacture of its own premium vaccines
and extends to working with domestic and overseas partners to create a healthy future for mankind.

Business Overview

SK bioscience has established a broad product portfolio and continues to invest in vaccine research,
which will be the driving force in the life science business going forward.
We will develop premium vaccines based on state-of-the-art technology and contribute to the promotion of public health.
Speed of Execution with Quality
SKYVAX Program

SK’s proprietary product supply to
developing countries including LMIC

Platform Technology
  • - Contractual development & manufacturing service
  • - Technology transfer to local manufacture including JV model
Manufacturing Versatility

Out-licensing or co-development
for US and Europe market for next decade

Market Leading Sales
/ Marketing Infrastructure
  • Joint sales and consignment production
    based on leading position
    in domestic vaccine market
Share Innovation

Key milestones of SK bioscience

  • 2009
    • Out-licensed CSL’s NBP601 (hemophilia drug), Korea’s first bio-pharmaceutical drug
  • 2013
    • Established partnership with IVI (International Vaccine Institute)
      to collaborate on the development of a new typhoid conjugate vaccine
  • 2014
    • Established strategic partnership with Sanofi Pasteur for co-development of next-generation pneumococcal conjugate vaccine
  • 2015
    • Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine
  • 2016
    • Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine
    • Gained approval for SKYPneumo, the first domestically produced PCV13 vaccine
  • 2017
    • Launched Sky Zoster Inj.,
      world’s second shingles vaccine
    • Signed agreement with international organization PATH to develop and produce pediatric enteritis vaccine
      for developing countries
  • 2018
    • SKY Varicella Inj. licensed to market, Korea’s second chickenpox vaccine
    • Signed an agreement with Sanofi Pasteur to license out cell-culture technology for producing cell culture-derived influenza vaccines
  • 2019
    • Gained WHO PQ for SKY Cellflu prefilled syringe/ SKY Cellflu Quadrivalent prefilled syringe (world’s first for cell-cultured influenza vaccine)
    • Gained WHO PQ for SKY Varicella Inj.
      as world’s second
  • 2020
    • Announced as WAVE2 by CEPI with GBP510 (COVID-19 vaccine)
    • Started clinical trial for in-house produced COVID-19 vaccine (GBP510, NBP2001)
    • Started phase 2 clinical trial for the next-generation pneumococcal conjugate vaccine co-developed with Sanofi Pasteur
    • Signed CMO agreement with AstraZeneca for the consigned production of COVID-19 vaccine
    • Signed CDMO agreement with Novavax for COVID-19 vaccine
  • 2021
    • Started phase 3 trial for COVID-19 vaccine candidate 'GBP510'
    • Funded to develop a vaccine candidate against COVID-19 (SARS-CoV-2) variants (CEPI)
    • Submitted application for export permit of typhoid vaccine co-developed with IVI
    • Signed licensing & purchase agreement for Novavax’s COVID-19 vaccine candidate (Novavax, KDCA)
    • Obtain EU-GMP Certification for COVID-19 Vaccine Facilities
  • 2022
    • Signed Advance Purchase Agreement of GBP510(KDCA)
    • Agreed SKYvaricella distribution(PAHO)
    • Achieved Turkish GMP Certification (TITCK)
    • Achieved BLA of SKYTyphoid for export
    • Published first ESG report
    • Achieved BLA of SKYCovione (KMFDS)

Business field

Process development
Bio R&D center
  • Various platform technologies for diverse vaccine types
  • Process development team
  • Evaluation/analysis team
  • Bacterial vaccine team
  • Viral vaccine team
  • New project team
Development & commercial manufacturing
L House
  • Pioneer in successful adaptation of ‘single-use system’ for vaccines on commercial scale
  • ‘Multi-modular system’ for diverse vaccine types
  • Flexibility using single-use System

  • Diverse platforms

  • Future expansion

Professional sales/marketing
Professional
  • Specialized sales/marketing infrastructure make company the leader in the domestic vaccine market
  • Various consignment production systems increase the convenience of vaccination
  • Unified system from licensing to selling

  • Specialized strategies for public/private market

  • Portfolio for all ages,
    from infants to elderly